Avanir jumps 85% on Alzheimer's data despite lack of details
This article was originally published in Scrip
Avanir Pharmaceuticals closed up 85.3% at $12.49 per share on 15 September after AVP-923 significantly reduced agitation associated with Alzheimer's disease in a 220-patient Phase II clinical trial even though the company did not disclose detailed safety and efficacy results.
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.